SCHEMBL1481591

SCHEMBL1481591

CCn1cc(-c2ccc(Cl)cc2Cl)nc1/C=C/c1ccc(-c2ccc(OCCCC(=O)O)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 7/20 0.44
FFAR1 O14842 6/20 0.44
CYP2C9 P11712 1/20 0.41
SCN5A Q14524 1/20 0.41
PPARA Q07869 3/20 0.41
ALB P02768 1/20 0.40
AGER Q15109 1/20 0.40
CNR1 P21554 2/20 0.39
CYSLTR2 Q9NS75 2/20 0.39
CYSLTR1 Q9Y271 2/20 0.39
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
DHODH Q02127 1/20 0.37
FABP3 P05413 1/20 0.37
FABP4 P15090 1/20 0.37
KCNA3 P22001 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481594 1.00 FFAR4 (0.44) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1481279 0.97 PPARA (0.44) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1481280 0.97 PPARA (0.44) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1480939 0.97 PPARA (0.43) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1480941 0.97 PPARA (0.43) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1480920 0.97 ALB (0.46) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1481100 0.97 ALB (0.46) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1480918 0.97 ALB (0.46) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1481103 0.97 ALB (0.46) FFAR4FFAR1CYP2C9SCN5APPARA
SCHEMBL1481709 0.96 AGER (0.42) FFAR4FFAR1CYP2C9SCN5APPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US claimed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US claimed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ FFAR4 2604/4885FFAR1 1810/4885CYP2C9 704/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ FFAR4 2604/4885FFAR1 1810/4885CYP2C9 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.